Zymeworks names Leonard Presta to advisory board
This article was originally published in Scrip
Privately held biotherapeutics company Zymeworks, which is developing antibody and next-generation protein-based products, has appointed Dr Leonard Presta to its scientific advisory board. Prior to joining the Vancouver, Canada-based firm, Dr Presta was a distinguished fellow at big pharma Merck & Co, responsible for the protein engineering of all internal therapeutic antibodies. He has also previously held positions at biotechnology firm Genentech.